Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 32Neuroendocrine Tumors 15Neoplasms 12Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 8Carcinoma 7Tuberous Sclerosis 6Kidney Neoplasms 5Carcinoma, Hepatocellular 5Carcinoid Tumor 5Lymphoma 4Adenoma, Islet Cell 4Stomach Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Lymphangioleiomyomatosis 3Lung Neoplasms 3Colorectal Neoplasms 3Angiomyolipoma 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Seizures 2Neuroectodermal Tumors, Primitive 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

Bevacizumab 6Paclitaxel 5Leucovorin 5Irinotecan 5Fluorouracil 5napabucasin 4Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Ocoxin 3Imatinib Mesylate 3Drug Therapy 3palbociclib 2entinostat 2encorafenib 2Oxaliplatin 2Levoleucovorin 2Folfox protocol 2Everolimus 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2spartalizumab 1ribociclib 1repotrectinib 1pralsetinib 1pembrolizumab 1olaparib 1linifanib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Digestive System Neoplasms × Everolimus × Clear all
NCT01275222 2021-06-25

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Novartis

Phase 1/2 Completed
117 enrolled 18 charts
GastrointestinalSarcoma

Digestive System Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT00879333 2015-11-03

GRANITE-1

Novartis

Phase 3 Completed
656 enrolled 15 charts
Gastrointestinal

Digestive System Neoplasms, Stomach Diseases, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡